Therapy/Reticulose

AIDS Study Not To Commence until FDA Approval Is Obtained

Published in AIDS Weekly, February 20th, 1995

Advanced Viral Research Corporation, Miami, Florida, announced that the U.S. Food and Drug Administration (FDA) has instructed the company to cease all activities directly related to the previously announced pilot AIDS study assessing the effects of the company's drug Reticulose on the viral load of persons who have been diagnosed with HIV.

The study was to be conducted at a South Florida hospital.

Upon receipt of this information, the company instructed the physician conducting the study to cease immediately all activities related to the study. Based on information received by the company from the physician, the company believes that all activities...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-02-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry